Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00195689 | Safety and Efficacy of Adalimumab in Patients With Moderate to Severely Active Psoriatic Arthritis | PHASE3 | COMPLETED | 400 | — | — | Aug 1, 2003 | - | Aug 29, 2007 | 1 | United States |
| Name | Type | Description |
|---|---|---|
| Human anti-TNF monoclonal antibody/adalimumab | BIOLOGICAL | - |
Inclusion Criteria: * Subject completed study M02-518 or M02-570 Exclusion Criteria: * Subject prematurely discontinued study M02-518 or M02-570 * Female subject who is pregnant or breast-feeding or considering becoming pregnant * Subject considered by the investigator, for any reason, to be...